120 related articles for article (PubMed ID: 35239349)
21. Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents.
Qi H; Chen L; Liu B; Wang X; Long L; Liu D
Bioorg Med Chem Lett; 2014 Feb; 24(4):1108-10. PubMed ID: 24456902
[TBL] [Abstract][Full Text] [Related]
22. Cell surface receptor expression patterns in osteosarcoma.
Hassan SE; Bekarev M; Kim MY; Lin J; Piperdi S; Gorlick R; Geller DS
Cancer; 2012 Feb; 118(3):740-9. PubMed ID: 21751203
[TBL] [Abstract][Full Text] [Related]
23. Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs).
Lu Y; Mao F; Li X; Zheng X; Wang M; Xu Q; Zhu J; Li J
J Med Chem; 2017 Jun; 60(12):5099-5119. PubMed ID: 28541695
[TBL] [Abstract][Full Text] [Related]
24. The emerging complexity of PDGFRs: activation, internalization and signal attenuation.
Rogers MA; Fantauzzo KA
Biochem Soc Trans; 2020 Jun; 48(3):1167-1176. PubMed ID: 32369556
[TBL] [Abstract][Full Text] [Related]
25. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
[TBL] [Abstract][Full Text] [Related]
26. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571.
Yoshitani K; Honoki K; Morishita T; Kido A; Miyauchi Y; Mii Y; Takakura Y
In Vivo; 2003; 17(3):255-8. PubMed ID: 12929576
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.
Gobin B; Moriceau G; Ory B; Charrier C; Brion R; Blanchard F; Redini F; Heymann D
PLoS One; 2014; 9(3):e90795. PubMed ID: 24599309
[TBL] [Abstract][Full Text] [Related]
28. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
Shawver LK; Schwartz DP; Mann E; Chen H; Tsai J; Chu L; Taylorson L; Longhi M; Meredith S; Germain L; Jacobs JS; Tang C; Ullrich A; Berens ME; Hersh E; McMahon G; Hirth KP; Powell TJ
Clin Cancer Res; 1997 Jul; 3(7):1167-77. PubMed ID: 9815796
[TBL] [Abstract][Full Text] [Related]
30. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
Pandey A; Volkots DL; Seroogy JM; Rose JW; Yu JC; Lambing JL; Hutchaleelaha A; Hollenbach SJ; Abe K; Giese NA; Scarborough RM
J Med Chem; 2002 Aug; 45(17):3772-93. PubMed ID: 12166950
[TBL] [Abstract][Full Text] [Related]
31. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
33. Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides.
Eldehna WM; El Kerdawy AM; Al-Ansary GH; Al-Rashood ST; Ali MM; Mahmoud AE
Eur J Med Chem; 2019 Feb; 163():37-53. PubMed ID: 30503942
[TBL] [Abstract][Full Text] [Related]
34. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D
Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
[TBL] [Abstract][Full Text] [Related]
35. Increased expression of platelet derived growth factor receptor β on trephine biopsies correlates with advanced myeloma.
Bilalis A; Pouliou E; Roussou M; Papanikolaou A; Tassidou A; Economopoulos T; Terpos E
J BUON; 2017; 22(4):1032-1037. PubMed ID: 28952224
[TBL] [Abstract][Full Text] [Related]
36. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
[TBL] [Abstract][Full Text] [Related]
37. Platelets promote osteosarcoma cell growth through activation of the platelet-derived growth factor receptor-Akt signaling axis.
Takagi S; Takemoto A; Takami M; Oh-Hara T; Fujita N
Cancer Sci; 2014 Aug; 105(8):983-8. PubMed ID: 24974736
[TBL] [Abstract][Full Text] [Related]
38. PDGFR-α, PDGFR-β, VEGFR-2 and CD117 expression in canine mammary tumours and evaluation of the in vitro effects of toceranib phosphate in neoplastic mammary cell lines.
Gattino F; Maniscalco L; Iussich S; Biasato I; Martano M; Morello E; Gola C; Millán Ruiz Y; Saeki N; Buracco P; Martín de Las Mulas J; De Maria R
Vet Rec; 2018 Aug; 183(7):221. PubMed ID: 29440590
[TBL] [Abstract][Full Text] [Related]
39. Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments.
Ehnman M; Missiaglia E; Folestad E; Selfe J; Strell C; Thway K; Brodin B; Pietras K; Shipley J; Östman A; Eriksson U
Cancer Res; 2013 Apr; 73(7):2139-49. PubMed ID: 23338608
[TBL] [Abstract][Full Text] [Related]
40. Novel 2-phenyl-3-(Pyridin-2-yl) thiazolidin-4-one derivatives as potent inhibitors for proliferation of osteosarcoma cells in vitro and in vivo.
Deng Y; Pi R; Niu L; Zhao Y; Ni D; Song L; Li Z; Han W; Wei Q; Han Y; Zhu T; Luo Z; Sun D; Dong S; Liu S
Eur J Med Chem; 2022 Jan; 228():114010. PubMed ID: 34861640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]